A prior study suggested that the therapeutic efficacy of methotrexate (MTX), the current “gold standard” treatment in experimental RA, was partly attributed to the increased development of CD4+CD25+ Treg cells [16]. The gene discussed is CD4; the disease is rheumatoid arthritis.